Market by Type, Technology, Age Group, Delivery Mode and Geography | Forecast 2019-2028
A Triton Market Research report has determined that the influenza vaccines market in the Middle East and Africa is set to surge at CAGR of 6.18% during the projected period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries scrutinized in the Middle East and Africa market are:
• Saudi Arabia
• United Arab Emirates
• Turkey
• South Africa
• Rest of Middle East & Africa
According to the Dubai government, the influenza vaccine immunization program is scheduled to offer a yearly influenza vaccine to infants older than six months, all children, adolescents and adults. The aging population and people suffering from diseases like diabetes, chronic pulmonary or cardiac diseases and chronic renal dysfunction must be given priority. Vaccination must also be prioritized for women after the first trimester of their pregnancy and for travelers traveling to a current outbreak area. Besides, for the household contacts of people in the high-risk group as well, vaccination is a suitable strategy. All these developmental strategies are indicating the growth of the influenza vaccines market in the UAE.
In Turkey, around 4.6% of the total GDP is spent on the healthcare sector. The central budget allocates approximately $15 billion for healthcare services. According to data provided by OECD (Organisation for Economic Co-operation and Development), the country’s healthcare expenditure per capita reached about $857, which is a 3.5 times rise since 2002. All these dedicated efforts by the government towards the development of the healthcare system are set to improve the demand for the influenza vaccines market in the country. This will help in the growth of the Turkish market.
Abbott is a healthcare company that is specialized in medical devices, diagnostics, nutritionals and generic medicines. The company is an expert in glucose monitoring, adult nutrition, blood and plasma screening, pediatric nutrition, point of care testing and remote heart failure monitoring. It offers different chronic pain devices and heart pumps.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. QUADRIVALENT IS THE DOMINANT TYPE OF INFLUENZA VACCINE
2.2.2. INJECTION IS FASTEST-GROWING DELIVERY MODE
2.2.3. CELL-BASED TECHNOLOGY IS RAPIDLY GROWING TECHNOLOGY IN THE MARKET
2.2.4. ADULT AGE GROUP IS MAJORLY CONTRIBUTING IN THE MARKET
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE
2.3.3. BARGAINING POWER OF SUPPLIERS
2.3.4. BARGAINING POWER OF BUYERS
2.3.5. INTENSITY OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1. ADVANCEMENT IN TECHNOLOGY
2.6.2. INITIATIVES TAKEN UP BY THE GOVERNMENT
2.7. MARKET RESTRAINTS
2.7.1. HIGH COST OF DEVELOPMENT
2.8. MARKET OPPORTUNITIES
2.8.1. GROWTH IN THE CASES OF INFLUENZA
2.9. MARKET CHALLENGES
2.9.1. COMPLEX DEVELOPMENT PROCESS
3. INFLUENZA VACCINES MARKET OUTLOOK - BY TYPE
3.1. QUADRIVALENT VACCINE
3.2. TRIVALENT VACCINE
4. INFLUENZA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
4.1. EGG-BASED TECHNOLOGY
4.2. CELL-BASED TECHNOLOGY
5. INFLUENZA VACCINES MARKET OUTLOOK - BY AGE GROUP
5.1. PEDIATRIC AGE GROUP
5.2. ADULT AGE GROUP
6. INFLUENZA VACCINES MARKET OUTLOOK - BY DELIVERY MODE
6.1. INJECTION
6.2. NASAL SPRAY
7. INFLUENZA VACCINES MARKET – MIDDLE EAST AND AFRICA
7.1. THE UNITED ARAB EMIRATES
7.2. TURKEY
7.3. SAUDI ARABIA
7.4. SOUTH AFRICA
7.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. MERCK SHARP & DOHME CORP
8.2. NOVARTIS AG
8.3. PFIZER INC
8.4. SANOFI
8.5. BIODIEM
8.6. EMERGENT BIOSOLUTIONS INC
8.7. F. HOFFMANN-LA ROCHE LTD
8.8. GLAXOSMITHKLINE PLC
8.9. ABBOTT
8.10. CSL LIMITED
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.1.1. OBJECTIVES OF STUDY
9.1.2. SCOPE OF STUDY
9.2. SOURCES OF DATA
9.2.1. PRIMARY DATA SOURCES
9.2.2. SECONDARY DATA SOURCES
9.3. RESEARCH METHODOLOGY
9.3.1. EVALUATION OF PROPOSED MARKET
9.3.2. IDENTIFICATION OF DATA SOURCES
9.3.3. ASSESSMENT OF MARKET DETERMINANTS
9.3.4. DATA COLLECTION
9.3.5. DATA VALIDATION & ANALYSIS
TABLE 1: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 4: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 5: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 6: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY SOURCE, 2019 & 2028 (IN %)
FIGURE 2: MIDDLE EAST AND AFRICA QUADRIVALENT INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 3: MIDDLE EAST AND AFRICA INJECTION DELIVERY MODEL MARKET, 2019-2028 (IN $ MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA CELL BASED TECHNOLOGY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA ADULT AGE GROUP MARKET, 2019-2028 (IN $ MILLION)
FIGURE 6: PORTER’S FIVE FORCE ANALYSIS
FIGURE 7: MARKET ATTRACTIVENESS INDEX
FIGURE 8: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY QUADRIVALENT VACCINE, 2019-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY TRIVALENT VACCINES, 2019-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY EGG-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY CELL-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY PEDIATRIC AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY ADULT AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY INJECTION, 2019-2028 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY NASAL SPRAY, 2019-2028 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 17: THE UNITED ARAB EMIRATES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: TURKEY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: SAUDI ARABIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: SOUTH AFRICA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: REST OF MIDDLE EAST & AFRICA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)